1. Schulman CC; Zlotta AR; Denis L; Schroder FH; Sakr WA. Prevention of prostate cancer. Scand J Urol Nephrol Suppl 2000;(205):50-61 2. Montironi R; Mazzucchelli R; Marshall JR; Bartels PH. Prostate cancer prevention: review of target populations, pathological biomarkers, and chemopreventive agents. J Clin Pathol 1999 Nov;52(11):793- 3. De Marzo AM, Coffey DS, Nelson WG. New concepts in tissue specific for prostate cancer and bening prostatic hyperplasia. Urology 1999; 53 (suppl 3): 29-42 4. Chokkalingam AP, Adamis HO, Nyren O, Johansson JE, Gridley G et al. Prostate carcinoma subsequent to diagnosis of bening prostatic hyperplasia. A population based cohort study in Sweden. Cancer 2003 5. Nelson WG; De Marzo AM; De Weese TL. The molecular pathogenesis of prostate cancer: Implications for prostate cancer prevention. Urology 2001 Apr;57(4 Suppl 1):39-45. 6. Di Silverio F, Gentile V, de Matteis et al. Distribution of inflammation, premalignant lesions, incidental carcinoma in histologically confirmed bening hyperplasia: a retrospective analysis. Eur Urol 2003; 43 (2): 164-75. 7. Kalra P, Togami J, Bansal B S G, Partin AW, Brawer MK, Babaian RJ, Ross LS, Niederberger CS. A neurocomputational model for prostate carcinoma detection Cancer. 2003 Nov 1; 98(9): 1849-54. 8. Chokkalingam AP, Nyren O, Johansson JE, Gridley G, McLaughlin JK, Adami HO,Hsing AW Prostate carcinoma risk subsequent to diagnosis of benign prostatic hyperplasia: a population-based cohort study in Sweden. . Cancer. 2003 Oct 15; 98(8): 1727-34. 9. Herranz Amo F, Arias Funez F, Arrizabalaga Moreno M, Calahorra Fernandez FJ, Carballido Rodriguez J, Diz Rodriguez R, Herrero Payo JA, Llorente Abarca C, Martin Martinez JC, Martinez-Pineiro Lorenzo L, Minguez Martinez R, Moreno Sierra J, Rodriguez Antolin A, Tamayo Ruiz JC, Turo Antona J. Prostate cancer in the Community of Madrid in the year 2000. III. Study of tumor extent. Actas Urol Esp. 2003 Jun; 27(6): 411-7. 10. Moller T, Anderson H, Aareleid T, Hakulinen T, Storm H, Tryggvadottir L, Corazziari I, Mugno E; EUROPREVAL Working Group. Cancer prevalence in Northern Europe: the EUROPREVAL studyAnn Oncol. 2003 Jun; 14(6): 946-57. 11. Reyes AO, Swanson PE, Carbone JM, Humphrey PA. Unusual histologic types of high-grade prostatic intraepithelial neoplasia. Am J Surg Pathol 1997 Oct;21(10):1215-1222. 12. Myers RB, Grizzle WE. Changes in biomarker expression in the development of prostatic adenocarcinoma. Biotech Histochem 1997 Mar;72(2):86-95. 13. Regueiro Lopez JC; Moreno Arcas P; Leva Vallejo M; Prieto Castro R; Anglada Curado FJ; Blanco Espinosa A; Lopez Beltran A; Requena Tapia MJ [Incidence of high grade prostatic intraepithelial neoplasia in urologic practice], [Incidencia de la neoplasia intraepitelial prostatica de alto grado en la practica urologica.]. Actas Urol Esp 2000 Jun;24(6):446-51. 14. Epstein JI; Potter SR. The pathological interpretation and significance of prostate needle biopsy findings: implications and current controversies. J Urol 2001 Aug;166(2):402-10. 15. Meng MU, Shinohara K, GrossfeldBD. Significance of high-grade prostatic neoplasia on prostate biopsia. Urol Oncol 2003; 21(2): 145-51; 16. Bhanot S, Gopalakrishan R, Oliver RT. Post biopsy in serum PSA. A potential tool for dynamics evolution of prostate cancer/ prostatic intraepithelial neoplasm (PIN). Cancer Biol Ther 2003; 2(1): 67-70 . 17. Yang CR, Qu YC, Ho HC, Kao YL, Cheng CL et al. Unsuspected prostate carcinoma and prostatic intrepithelial neoplasm in Taiwanese patients undergoing cystoprostatectomy. Mol Urol 1999; 3 (1): 33-39) 18. Bartels PH; Montironi R; Duval da Silva V; Hamilton PW; Thompson D; Vaught L; Bartels HG. Tissue Architecture Analysis in Prostate Cancer and Its Precursors: An Innovative Approach to Computerized Histometry. Eur Urol 1999 May-Jun; 35(5-6):484-491 19. Iczkowski KA; Bostwick DG. Prostate biopsy 1999: strategies and significance of pathological findings. Semin Urol Oncol 1999 Nov; 17(4): 177-86. 20. Goeman L, Joniau S, Ponette D, Roskams F Van der Aa, T, Oyen R and Poppel. H Van Is low-grade prostatic intraepithelial neoplasia a risk factor for cancer? Prostate cancer and prostatic disease. 2003; 6(4): 305-10. 21. Narod SA, Dupont A, Cusan L, Diamond P, Gomez JL, Suburu R, et al. The impact of family history on early detection of prostate cancer. Nature Med 1995; 1:99–101. 22. Matikainen MP; Schleutker J; Morsky P; Kallioniemi OP; Tammela TL. Detection of subclinical cancers by prostate-specific antigen screening in asymptomatic men from high-risk prostate cancer families. Clin Cancer Res 1999 Jun;5(6):1275-9. 23. Simard J, Dumont M, Labuda D, Sinnett D, Meloche C, El-Alfy M, Berger L, Lees E, Labrie F, Tavtigian SV Prostate cancer susceptibility genes: lessons learned and challenges posed. Endocr Relat Cancer. 2003 Jun;10 (2):225-59. 24. Crawford ED. Epidemiology of prostate cancer. Urology. 2003 Dec 22; 62(6 Suppl 1): 3-12. 25. Hsieh K, Albertsen PC. Populations at high risk for prostate cancer. Urol Clin North Am. 2003 Nov; 30(4): 669-76. 26. Paul Lichtenstein, Niels V. Holm, Pia K. VerkasaloAnastasia Iliadou, Jaakko Kaprio, Markku Koskenvuo, Eero Pukkala, Axel Skytthe, and Kari Hemminki. Environmental and Heritable Factors in the Causation of Cancer — Analyses of Cohorts of Twins from Sweden, Denmark, and Finland. The N J M. 2000; Volume 343:78-85. 27. Huiatt RA, Armstrong MA, Klatsky AL, Sidney S: Alcohol consumption, smoking, and other risk factors and prostate cancer in a large health plan cohort in California, United States. Cáncer Causes Control 1994; 5: 66-72. 28. Klaunig JE, Xu Y, Han C, Kamendulis LM, Chen J, Heiser C, et al. The effect of tea consumption on oxidative stress in smokers and nonsmokers. Proc Soc Exp Biol Med 1999; 249–54. 29. Platz EA, Rimm EB, Kawachi I, Colditz GA, Stampfer MJ, Willet WC and Giovannucci E. Alcohol cosumption, cigarrette smoking, and risk of bening prostatic hyperplasia. Am J Epidemiol 1999; 149 (2): 106-115 30. Giovannucci E, Rimm EB, Ascheiro A, Graham A et al. Smoking and risk of total fatal Prostate Cancer in United States Health professionals. CEBP 1999; 8(4): 277-82 31. Bouffioux L, Willems E, Waltregny D. .Can the development of prostate cancer be prevented?. Rev Med Liege. 2003 Apr; 58(4):240-6. 32. Foster CS; Bostwick DG; Bonkhoff H; Damber JE; van der Kwast T; Montironi R; Sakr WA.. Cellular and molecular pathology of prostate cancer precursors. Scand J Urol Nephrol Suppl 2000; (205): 19-43. 33. Le marchand L, Kolonel LN, Yoshizawa CN. Lifetime occupational physical activity and prostate cáncer risk. Am J Epidemiol 1999, 133: 103-11. 34. Hoyo C, Reid ML, Godley PA, Parrish T, Smith L, Gammon M. Barriers and strategies for sustained participation of African-American men in cohort studies. Ethn Dis. 2003 Fall; 13(4): 470-6. 35. Stone SN, Hoffman RM, Tollestrup K, Stidley CA, Witter JL, Gilliland FD. Family history, Hispanic ethnicity, and prostate cáncer risk. Ethn Dis. 2003 Spring; 13(2): 233-9.. 36. Bodiwala D, Luscombe CJ, French ME, Liu S, Saxby MF, Jones PW, Fryer AA, Strange RC. Associations between prostate cancer susceptibility and parameters of exposure to ultraviolet radiation. Cancer Lett. 2003 Oct 28; 200(2): 141-8. 37. Platz EA, Rimm EC, Willet WC, Kantoff PH, Giovannucci E. Racial variation in prostate cancer incidence in hormonal system markers among male health professionals. J Natl Cancer Inst 2000; 92: 2009-17)
|